Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines? Journal Article

   

Authors:	Burstein, H. J.; Piccart-Gebhart, M. J.; Perez, E. A.; Hortobagyi, G. N.; Wolmark, N.; Albain, K. S.; Norton, L.; Winer, E. P.; Hudis, C. A.
Article Title:	Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?
Keywords:	protein expression; overall survival; cancer recurrence; doxorubicin; fluorouracil; drug efficacy; risk benefit analysis; note; paclitaxel; disease free survival; chemotherapy, adjuvant; breast cancer; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; cyclophosphamide; food and drug administration; breast neoplasms; docetaxel; heart failure; adjuvant chemotherapy; cardiotoxicity; epirubicin; receptor, erbb-2; trastuzumab; navelbine; anthracycline; dna topoisomerase (atp hydrolysing); anthracyclines; molecular targeted therapy; antibodies, monoclonal, humanized
Journal Title:	Journal of Clinical Oncology
Volume:	30
Issue:	18
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2012-06-20
Start Page:	2179
End Page:	2182
Language:	English
DOI:	10.1200/jco.2012.42.0695
PROVIDER:	scopus
PUBMED:	22614986
PMCID:	PMC6076002
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84864018416&partnerID=40&md5=d437b2de54c6ec906b2c7861e276b958
Notes:	--- - "Export Date: 1 August 2012" - "CODEN: JCOND" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/31823